BioSpace News Archive

Qualigen Therapeutics, Inc. announces that two abstracts featuring the Company’s pan-RAS inhibitor program will be included in the American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting Abstract Book.

Spesana has announced the formation of the Spesana Advisory Board with appointments of experienced industry leaders across clinical sites, life science companies and diagnostic labs.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked first in patient centricity, integrity, ease of relations and transparency in pricing by patient groups who worked with the company around the world.

Nutcracker Therapeutics, Inc. will present at this year’s TIDES USA, or the Oligonucleotide and Peptide Therapeutics conference, being held May 7-10, 2023 in San Diego, CA.

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure Device System.

Personalis, Inc. announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial, B-STRONGER-1, to evaluate the clinical performance of the NeXT Personal® test for detecting minimal residual disease during and after treatment and recurrent cancer in patients with early-stage resectable triple-negative breast cancer.

Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies.

Tris Pharma, Inc. today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jeff Keyes as its new Chief Financial Officer, effective May 15, 2023.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).